| Income | — | — |
| Revenue from operations | 23.41a | 19.05a |
| Other income | 2.71a | 1.44a |
| Total income | 26.13a | 20.49a |
| Expenses | — | — |
| Purchase of drugs, consumables and implants | -4.3a | -3.54a |
| Change in inventories of drugs, consumables and implants | -0.01a | -0.05a |
| Employee benefit expenses | -4.48a | -3.72a |
| Professional and consultancy fees | -4.23a | -3.7a |
| Finance costs | -0.52a | -0.52a |
| Depreciation and amortization expense | -1.17a | -1.13a |
| Other expenses | -2.77a | -2.29a |
| Total expenses | -17.48a | -14.86a |
| Profit before tax | 8.65a | 5.63a |
| Tax expense/(credit) | — | — |
| Current tax | -1.47a | -1.12a |
| Deferred tax charge/(credit) | -0.31a | -2.43a |
| Total tax expense/(credit) | -1.78a | -1.31a |
| Profit for the year | 6.87a | 6.94a |